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Summary
Background Numerous randomised trials have compared coronary artery bypass grafting (CABG) with percutaneous 
coronary intervention (PCI) for patients with coronary artery disease. However, no studies have been powered to 
detect a difference in mortality between the revascularisation strategies.
Methods We did a systematic review up to July 19, 2017, to identify randomised clinical trials comparing CABG 
with PCI using stents. Eligible studies included patients with multivessel or left main coronary artery disease who 
did not present with acute myocardial infarction, did PCI with stents (bare-metal or drug-eluting), and had more 
than 1 year of follow-up for all-cause mortality. In a collaborative, pooled analysis of individual patient data from 
the identified trials, we estimated all-cause mortality up to 5 years using Kaplan-Meier analyses and compared PCI 
with CABG using a random-effects Cox proportional-hazards model stratified by trial. Consistency of treatment 
effect was explored in subgroup analyses, with subgroups defined according to baseline clinical and anatomical 
characteristics.
Findings We included 11 randomised trials involving 11 518 patients selected by heart teams who were assigned to PCI 
(n=5753) or to CABG (n=5765). 976 patients died over a mean follow-up of 3·8 years (SD 1·4). Mean Synergy between 
PCI with Taxus and Cardiac Surgery (SYNTAX) score was 26·0 (SD 9·5), with 1798 (22·1%) of 8138 patients having a 
SYNTAX score of 33 or higher. 5 year all-cause mortality was 11·2% after PCI and 9·2% after CABG (hazard ratio 
[HR] 1·20, 95% CI 1·06–1·37; p=0·0038). 5 year all-cause mortality was significantly different between the 
interventions in patients with multivessel disease (11·5% after PCI vs 8·9% after CABG; HR 1·28, 95% CI 1·09–1·49; 
p=0·0019), including in those with diabetes (15·5% vs 10·0%; 1·48, 1·19–1·84; p=0·0004), but not in those without 
diabetes (8·7% vs 8·0%; 1·08, 0·86–1·36; p=0·49). SYNTAX score had a significant effect on the difference between 
the interventions in multivessel disease. 5 year all-cause mortality was similar between the interventions in patients 
with left main disease (10·7% after PCI vs 10·5% after CABG; 1·07, 0·87–1·33; p=0·52), regardless of diabetes status 
and SYNTAX score.
Interpretation CABG had a mortality benefit over PCI in patients with multivessel disease, particularly those with 
diabetes and higher coronary complexity. No benefit for CABG over PCI was seen in patients with left main disease. 
Longer follow-up is needed to better define mortality differences between the revascularisation strategies.
Funding None.
Introduction
Numerous randomised trials1–3 have compared coronary 
artery bypass grafting (CABG) with percutaneous coronary 
intervention (PCI) with balloon angioplasty, bare-metal 
stents, or drug-eluting stents for the treatment of multi-
vessel or left main coronary artery disease. In 2009, Hlatky 
and colleagues1 reported the results of a pooled analysis 
of individual patient data from ten randomised trials 
involving 7812 patients assigned to CABG or PCI with 
balloon angioplasty or bare-metal stents. In that study, 
5 year mortality was 8·4% after CABG and 10·0% 
after PCI (p=0·12). More recent trials4–10 comparing 
CABG with PCI with drug-eluting stents have found 
similar mortality for the revascularisation strategies. 
However, to date, no clinical trial has been sufficiently 
powered to detect a difference in all-cause mortality 
between CABG and PCI using stents.
To overcome this limitation, we did a pooled analysis 
of individual-patient data from randomised trials 
comparing CABG with PCI using stents to examine the 
comparative effects of these interventions on long-term 
all-cause mortality in all patients with coronary artery 
disease and separately in patients with multivessel or left 
main disease.
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Methods
Study selection and data collection
We searched MEDLINE, Embase, and the Cochrane 
Library up to July 19, 2017, using the search terms 
“coronary artery bypass grafting”, “percutaneous coronary 
inter vention”, “stent”, and “random*”. Two researchers 
(SJH and MM) independently identified randomised trials 
comparing CABG with PCI in which patients had 
multivessel or left main coronary artery disease and did 
not present with acute myocardial infarction, PCI was 
done with stents (bare-metal or drug-eluting) and not 
balloon angioplasty, and more than 1 year follow-up for 
all-cause mortality was available (appendix). Abstracts 
from meetings were not considered, nor were unpublished 
trials. Reference lists from potentially relevant articles 
were checked to ensure no studies were missed.
We contacted the principal investigators of the eligible 
trials to obtain individual patient data for pooled analyses; 
data were provided in a standardised spreadsheet. 
Data were cross-checked against the publication of the 
primary endpoint and long-term follow-up publications. 
Several minor inconsistencies were resolved through 
consensus with trial principal investigators. Baseline and 
procedural characteristics of individual trials are presented 
in the appendix with information about missing data for 
certain characteristics. 
We assessed the quality of individual trials using 
the Cochrane Collaboration’s tool for assessing risk 
of bias.11 Each trial was approved by its local medical 
ethics committee, and all patients provided written 
informed consent.
Outcomes and follow-up
To allow a consistent definition of follow-up among trials, 
the duration of follow-up was calculated from the day of 
the procedure. If patients died before the procedure, the 
time from randomisation to death was used to calculate 
the duration of follow-up.
All-cause mortality was the primary endpoint of this 
study, with analyses planned in all patients and separately 
in patients with multivessel disease or left main disease. 
The multivessel disease group consisted of patients with 
multivessel disease without left main disease, whereas 
the left main disease group consisted of patients with 
any left main disease, irrespective of the number of 
diseased vessels.
We also planned separate analyses for trials that used 
bare-metal stents, those that used drug-eluting stents, 
those that used first-generation drug-eluting stents, and 
those that used newer-generation drug-eluting stents. 
First-generation drug-eluting stents released paclitaxel or 
sirolimus. Newer-generation drug-eluting stents released 
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Research in context
Evidence before this study
We searched MEDLINE, Embase, and the Cochrane Library up to 
July 19, 2017, to identify randomised clinical trials comparing 
coronary artery bypass grafting (CABG) with percutaneous 
coronary intervention (PCI) using stents. We used the search terms 
“coronary artery bypass grafting”, “percutaneous coronary 
intervention”, “stent”, and “random*”. Studies were included if the 
patients had multivessel or left main coronary artery disease and 
did not present with acute myocardial infarction, PCI was done 
with bare-metal or drug-eluting stents and not balloon 
angioplasty, and more than 1 years’ follow-up for all-cause 
mortality was available. We identified 12 high-quality trials. 
One trial found a survival benefit of CABG over PCI with bare-metal 
stents for multivessel disease at 6 years’ follow-up. Another trial 
found better survival at 5 years’ follow-up with CABG than with 
PCI using first-generation drug-eluting stents in patients with 
multivessel disease and diabetes. However, these results have not 
been reproduced in other individual trials with 3–10 years’ 
follow-up, except in underpowered and hypothesis-generating 
subgroup analyses. Two pooled analyses of CABG versus PCI with 
balloon angioplasty or bare-metal stents for multivessel disease 
found conflicting results, and what the survival differences are 
between CABG and PCI remains largely unclear.
Added value of this study
This study is the largest analysis of patients randomly 
assigned to PCI using stents or to CABG. To our knowledge, 
this study shows for the first time that all-cause mortality is 
significantly lower with CABG than with PCI in an overall 
randomised population of patients with multivessel or left 
main coronary artery disease. Additionally, the use of 
individual patient data allowed identification of important 
subgroups that have a survival benefit from CABG. These 
subgroups include patients with multivessel disease and 
diabetes and those with higher coronary lesion complexity 
(established with the Synergy between PCI with Taxus and 
Cardiac Surgery [SYNTAX] score). Patients with left main 
disease had similar survival with PCI and CABG, regardless of 
diabetes and SYNTAX score.
Implications of all the available evidence
Some patients have specific indications for PCI or CABG, 
such as coronary complexity too high for PCI or operative 
risk too high for CABG. In patients with estimated clinical 
equipoise, as determined by heart teams, consideration of 
disease type (multivessel or left main), coronary complexity, 
and diabetes status is crucial because these are important 
treatment effect modifiers of favourable mortality after 
CABG versus PCI and should affect decisions on coronary 
revascularisation in daily practice. However, longer follow-up 
of randomised trials is needed to better define mortality 
differences in overall patients and specific subgroups.
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everolimus, zotarolimus, or biolimus. The VA CARDS 
trial7 (Co operative Studies Program study number 557) 
was excluded from the separate analyses of first-generation 
and newer-generation drug-eluting stents because a 
mixture of these stents was used.
We prespecified subgroups for analyses according to 
the baseline characteristics sex, age, body-mass index, 
hyper tension, hypercholesterolaemia, diabetes, peripheral 
vascular disease, previous myocardial infarction, left-
ventricular ejection fraction, and core laboratory-assessed 
Synergy between PCI with Taxus and Cardiac Surgery 
(SYNTAX) score (as a measure of lesion complexity).12 
Post-hoc subgroup analyses were done according to 
SYNTAX score tertiles in the groups of patients with or 
without diabetes.
In all trials, a Clinical Events Committee adjudicated 
the events.
Statistical analysis
A team consisting of three epidemiologists and stati-
sticians (MM, EB, and GP) did the statistical analyses. All 
analyses were done by intention to treat. Baseline, 
procedural, and outcome data for individual patients were 
pooled. Continuous variables are presented as mean (SD) 
and were compared with t tests; discrete data are presented 
as frequencies and were compared with χ² tests.
We pooled data from all trials to provide unadjusted 
Kaplan-Meier estimates of all-cause mortality at 5 years 
follow-up and for landmark analyses at 30 days and 
between 31 days and 5 years. Subgroup analyses were 
done with follow-up data at 5 years only. PCI and CABG 
were compared with random-effects Cox proportional-
hazards models stratified by trial and with inclusion of 
a γ frailty term to account for heterogeneity between trials. 
Trial heterogeneity is captured in random-intercept frailty 
terms, which quantify trial-specific deviation from the 
average hazard ratio (HR). Frailties are unobserved 
factors, distributed as γ random variables with a mean of 1 
and variance (θ). Hence, the variance of the frailty terms 
represents heterogeneity in baseline risk between trials. 
The significance of the variance parameter was assessed 
with the likelihood ratio test. The proportional hazards 
assumption in the Cox model for the overall group was 
assessed by visual inspection of the scaled Schoenfeld 
residuals over a Kaplan-Meier transform of time, as well 
as with the corresponding test for the correlation of 
the Schoenfeld residuals with time, and was not violated 
(p=0·12). Nevertheless, visual inspection of the Kaplan-
Meier curves suggested a time-dependent variance in the 
HR of PCI versus CABG and, therefore, models that 
allowed for a time-varying HR were also done. For these 
models, we assumed a single cutoff point, allowing the 
HR to have different values before and after the cutoff. 
The cutoff was selected on the basis of visual inspection 
of the scaled Schoenfeld residuals. Subgroup analyses 
according to baseline clinical, procedural, and anatomical 
characteristics were also done with the Cox models.
A two-sided p value of less than 0·05 was considered to 
indicate statistical significance; we did not adjust for 
multiplicity. All statistical analyses were done with SPSS 
software, version 21, or R software, version 3.2.4.
PCI (n=5753) CABG (n=5765) p value
Age (years) 63·6 (9·8; 5753) 63·7 (9·9; 5765) p=0·72
Sex
Female 23·9% (1373/5753) 23·8% (1371/5765) p=0·91
Male 76·1% (4380/5753) 76·2% (4394/5765) p=0·91
Body-mass index >30 kg/m² 28·1% (1548/5506) 28·3% (1558/5511) p=0·82
Current smoker 22·3% (1274/5701) 22·3% (1273/5703) p=0·97
Diabetes 38·5% (2215/5753) 37·7% (2171/5765) p=0·35
Insulin treated 12·9% (545/4234) 11·9% (504/4245) p=0·16
Hypertension 67·6% (3880/5739) 68·1% (3913/5748) p=0·59
Hypercholesterolaemia 69·5% (3982/5726) 67·3% (3862/5735) p=0·0112
Peripheral vascular disease 8·2% (424/5158) 8·5% (440/5164) p=0·58
Carotid artery disease 7·8% (161/2072) 8·1% (168/2074) p=0·69
Previous TIA or CVA 5·4% (218/4052) 6·2% (253/4054) p=0·098
Previous myocardial infarction 28·0% (1438/5138) 27·5% (1417/5156) p=0·57
Left-ventricular ejection fraction
Moderate (30–49%) 15·2% (807/5303) 14·3% (779/5430) p=0·20
Poor (<30%) 0·9% (49/5303) 1·0 (54/5430) p=0·71
Unstable angina pectoris 34·6% (1786/5158) 34·2% (1767/5160) p=0·68
Three-vessel disease* 58·6% (2460/4201) 61·8% (2594/4197) p=0·063
Left main disease 38·8% (2233/5753) 38·9% (2245/5765) p=0·89
SYNTAX score 26·0% (9·3; 4081) 26·0% (9·8; 4057) p=0·91
0–22 37·6% (1533/4081) 39·1% (1585/4057) p=0·16
23–32 41·1% (1677/4081) 38·1% (1545/4057) p=0·0053
≥33 21·3% (871/4081) 22·8% (927/4057) p=0·10
Type of stent used in PCI†
Bare-metal stent 26·6% (1490/5610) .. ..
Drug-eluting stent 73·4% (4120/5610) .. ..
First-generation 39·2% (2199/5610) .. ..
Newer-generation 34·2% (1920/5610) .. ..
Number of stents used in PCI 3·1 (2·0; 4935) .. ..
CABG procedure
Left internal mammary artery .. 96·2% (4574/4753) ..
Bilateral internal mammary artery .. 18·7% (771/4122) ..
Off-pump .. 27·5% (1085/3945) ..
Medication at discharge
Aspirin 97·3% (4487/4612) 95·5% (3814/3994) p<0·0001
Thienopyridine 96·7% (4479/4630) 45·1% (1815/4026) p<0·0001
Dual antiplatelet therapy 95·1% (4384/4612) 44·0% (1759/3994) p<0·0001
Statin 88·1% (3052/3464) 84·0% (2843/3384) p<0·0001
β blocker 79·1% (2741/3464) 76·2% (2557/3356) p=0·0040
ACE inhibitor or ARB 63·7% (2205/3464) 46·9% (1588/3383) p<0·0001
Calcium-channel blocker 27·7% (959/3463) 21·8% (736/3383) p<0·0001
Data are mean (SD; n) or % (n/N). PCI=percutaneous coronary intervention. CABG=coronary artery bypass grafting. 
TIA=transient ischaemic attack. CVA=cerebrovascular attack. SYNTAX=Synergy between PCI with Taxus and Cardiac 
Surgery. ACE=angiotensin-converting enzyme. ARB=angiotensin II receptor blocker. *Of the group of patients with 
multivessel disease. †Data are only for patients who underwent PCI; the type of drug-eluting stent used was not 
available for one patient enrolled in the VA CARDS trial.7
Table 1: Baseline, procedural, and discharge data of randomised cohorts
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Reporting of this individual patient-data, pooled 
analysis concurs with specific PRISMA guidelines.13 
This study is not registered and no protocol has been 
published.
Role of the funding source
This study was done without funding, although individual 
trials were sponsored. The decision to submit the 
manuscript for publication was made by consensus among 
the principal investigators of the individual trials. Sponsors 
of the individual trials were involved in data collection in 
the trials, but were not involved in data analyses, data 
interpretation, or drafting of this manuscript.
Results
We identified 19 relevant trials in the literature search, of 
which seven were excluded because patients did not have 
multivessel or left main disease (n=4), only 54% of PCI 
procedures were done with a stent (n=1), or follow-up 
was only available up to 1 year (n=2; appendix). The 
principal investigators of the remaining 12 trials4–10,14–18 
were contacted to obtain individual patient data for a 
pooled analysis; one trial14 involving 105 patients was 
unable to provide data. All trials were considered to be of 
high quality according to criteria, despite being unable to 
mask investigators and patients to treatment allocation 
(appendix).
In the 11 trials that provided data, 11 518 patients 
selected by heart teams were randomly assigned to 
CABG (n=5765) or to PCI (n=5753). PCI was done with 
bare-metal stents in 1490 patients in four trials (n=3051), 
with first-generation drug-eluting stents in 2199 patients 
in four trials (n=4498), and with newer-generation drug-
eluting stents in 1920 patients in three trials (n=3969; 
table 1). CABG was done with a left internal mammary 
artery in 4574 patients in nine trials (n=4753), with a 
bilateral internal mammary artery in 771 patients in 
seven trials (n=4122), and off-pump in 1085 patients in 
seven trials (n=3945). SYNTAX scores were available 
from six trials and for 8138 patients (CABG: n=4057; PCI: 
n=4081). The mean SYNTAX score was 26·0 (SD 9·5), 
with 1798 (22·1%) patients having a SYNTAX score of 
33 or higher. Baseline, procedural, and discharge data 
for the patients are shown in table 1, and data for each 
trial and treatment crossovers are shown in the appendix. 
976 patients died during a mean follow-up of 3·8 years 
(SD 1·4). 5 year all-cause mortality was 11·2% (539 events) 
after PCI and 9·2% (437 events) after CABG (HR 1·20, 
95% CI 1·06–1·37; p=0·0038; figure 1, table 2). At 30 days’ 
follow-up, all-cause mortality was 1·3% (76 events) after 
PCI and 1·4% (78 events) after CABG (0·97, 0·71–1·33; 
p=0·84). Between 31 days’ and 5 years’ follow-up, all-
cause mortality was 10·0% (463 events) after PCI and 
8·0% (359 events) after CABG (1·26, 1·09–1·44; 
p=0·0009). A time-dependent model showed that the risk 
of mortality was similar for PCI and CABG during the 
first year of follow-up (0∙97, 0∙80–1∙19; p=0·80), but in 
favour of CABG beyond 1 year (1·39, 1·17–1·62; p<0·0001; 
appendix). The estimate of the frailty parameter for 
heterogeneity was significant (θ=0·39, p<0·0001).
Patients in trials in which drug-eluting stents were used 
were older, had more comorbidities, and were more likely 
to have diabetes, left main disease, and three-vessel 
disease than patients in trials in which bare-metal stents 
were used (table 3). 5 year all-cause mortality was 8·7% 
(131 events) after PCI and 8·2% (125 events) after CABG 
(HR 1·05, 95% CI 0·82–1·34; p=0·72) in trials that did 
PCI with bare-metal stents (including 3051 patients), and 
12·4% (408 events) after PCI and 10·0% (312 events) after 
CABG (1·27, 1·09–1·47; p=0·0017) in trials that did PCI 
with drug-eluting stents (including 8467 patients). The 
type of stent used (bare-metal vs drug-eluting) did not 
interact with the treatment effect (pinteraction=0·53).
Although there were significant differences in clinical 
and anatomical characteristics between the trials using 
first-generation drug-eluting stents and those using newer-
generation drug-eluting stents (table 3), the difference in 
5 year mortality between PCI and CABG was consistent 
when analysing the 4300 patients in the trials using first-
generation drug-eluting stents (13·2% [254 events] after 
PCI vs 11·1% [201 events] after CABG; HR 1·21, 95% CI 
1·01–1·46; p=0·0415) and the 3969 patients in the 
trials using newer-generation drug-eluting stents (10·3% 
[136 events] after PCI vs 7·9% [106 events] after CABG; 
1·27, 0·98–1·64; p=0·0658; pinteraction=0·78).
In subgroup analyses, diabetes was the only baseline 
characteristic with a significant treatment interaction 
(pinteraction=0·0077). In patients with diabetes, PCI was 
associated with higher 5 year all-cause mortality than was 
CABG (15·7% [278 events] vs 10·7% [185 events]; HR 1·44, 
95% CI 1·20–1·74; p=0·0001), whereas mortality did not 
differ between the interventions in patients without 
diabetes (8·7% [261 events] after PCI vs 8·4% [252 events] 
after CABG; 1·02, 0·86–1·21; p=0·81; table 2, figures 2, 3). 
Although the interaction was not significant 
(pinteraction=0·21), the mortality benefit of CABG over PCI 
Figure 1: Mortality after CABG versus after PCI during 5 years’ follow-up
Kaplan-Meier estimates are from the overall pooled patient population. PCI=percutaneous coronary intervention. 
CABG=coronary artery bypass grafting. HR=hazard ratio.
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tended to increase with increasing SYNTAX scores 
(table 2). A similar trend was found in subgroups of 
patients with or without diabetes (appendix).
644 of 7040 patients with multivessel disease assigned 
to PCI (n=3520) or to CABG (n=3520) died during a 
mean follow-up of 4·1 years (SD 1·4). 5 year all-cause 
mortality in patients with multivessel disease was higher 
after PCI than after CABG (11·5% [365 events] vs 8·9% 
[279 events]; HR 1·28, 95% CI 1·09–1·49; p=0·0019; 
figure 3, table 2). As observed for the overall patient 
cohort, the mortality benefit of CABG over PCI in 
patients with multivessel disease increased with duration 
of follow-up in time-dependent models (appendix). 5 year 
all-cause mortality was 15·5% (207 events) after PCI 
versus 10·0% (134 events) after CABG in the subgroup of 
patients with multivessel disease who had diabetes 
(HR 1·48, 95% CI 1·19–1·84; p=0·00037), and 8·7% 
(158 events) after PCI versus 8·0% (145 events) after 
CABG in the subgroup of those patients without diabetes 
(1·08, 0·86–1·36; p=0·49; pinteraction=0·0453; table 2). The 
mortality benefit of CABG over PCI increased with 
increasing SYNTAX scores in patients with multivessel 
disease (table 2).
322 of 4478 patients with left main disease assigned to 
PCI (n=2233) or to CABG (n=2245) died during a mean 
follow-up of 3·4 years (SD 1·4). 5 year all-cause mortality 
for patients with left main disease was 10·7% (174 events) 
after PCI and 10·5% (158 events) after CABG (HR 1·07, 
95% CI 0·87–1·33; p=0·52; figure 3, table 2). By contrast 
with the overall cohort and multivessel disease sub-
group, a benefit for CABG over PCI was not seen with 
longer follow-up in time-dependent models (appendix). 
Diabetes status did not interact with the treatment effect 
in patients with left main disease (pinteraction=0·13). 5 year 
all-cause mortality was 16·5% (71 events) after PCI versus 
13·4% (51 events) after CABG (HR 1·34, 95% CI 
0·93–1·91; p=0·11) in the subgroup of patients with left 
main disease who had diabetes, and 8·8% (103 events) 
after PCI versus 9·6% (107 events) after CABG (0·94, 
0·72–1·23; p=0·65) in the subgroup of those patients 
without diabetes (table 2). Subgroup analyses according 
to SYNTAX score in patients with left main disease 
showed that mortality from PCI and CABG did not differ 
according to score (table 2).
Discussion
This collaborative analysis of individual patient data 
from 11 randomised trials is the first large-scale study 
to compare CABG with PCI with stents. We found that 
5 year all-cause mortality was higher after PCI than 
after CABG in 11 518 patients. In subgroup analyses, 
CABG only had a mortality benefit over PCI in patients 
with multivessel disease and diabetes; no difference 
was seen in patients with multivessel disease without 
diabetes, nor in patients with left main disease (with or 
without diabetes). Coronary lesion complexity, assessed 
with the SYNTAX score, was an important effect 
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modifier in patients with multivessel disease, but did 
not appear to modify treatment effect in those with left 
main disease.
The relative benefits of CABG versus PCI with stents 
in terms of outcomes are highly debated, particularly 
each time stent design is enhanced. Improvements in 
stent design have led to inclusion of higher-risk patients 
with more complex disease, such as three-vessel or left 
main disease, in randomised trials. This higher-risk 
profile is also reflected in our data, wherein 5 year all-
cause mortality in both the CABG and PCI cohorts was 
higher in more recent trials with drug-eluting stents than 
in earlier trials with bare-metal stents, but a larger 
relative benefit of CABG over PCI was most likely due to 
more complex coronary artery disease.
In all of the included trials, both an interventional 
cardiologist and a cardiac surgeon had to assume clinical 
equipoise between PCI and CABG for patients to be 
randomised. Some patients were not eligible for 
inclusion in the selected trials because of having coronary 
lesion complexity too severe to be treated with PCI or 
operative risk deemed too high for CABG.19 The results 
of this analysis are not generalisable to the entire 
population of patients with coronary artery disease that 
require revascularisation. Therefore, heart team decision 
making is crucial to recommend the best revascularisation 
strategy for an individual patient.20
The mortality benefit of CABG over PCI in the overall 
group was retained over a variety of patient baseline 
characteristics. However, the presence of diabetes was an 
important modifier, as shown in previous analyses.1 The 
benefit of CABG in patients with diabetes might be 
attributed to more effective revascularisation of diffuse, 
complex coronary disease. This hypothesis is consistent 
with the findings of the subgroup analysis according to 
SYNTAX score. In the total cohort, a step-wise increase in 
the difference between CABG and PCI was observed with 
increasing SYNTAX scores. Other studies21 have also 
identified sex as an effect modifier, but we did not find a 
significant treatment-by-sex interaction for 5 year mortality.
Patients with multivessel disease had lower mortality 
with CABG than with PCI, consistent with the SYNTAX 
trial that compared CABG with PCI using first-generation 
drug-eluting stents.22,23 The BEST trial,8 in which second-
generation everolimus-eluting stents were used to treat 
multivessel disease, also found that CABG was associated 
with a lower incidence of major adverse cardiac or 
cerebrovascular events, driven by a reduced incidence of 
myocardial infarction and repeat revascularisation. Large 
real-world registries have applied propensity score 
Trials with 
bare-metal stents 
(n=3051)
Trials with 
drug-eluting stents 
(n=8467)
p value Trials with 
first-generation 
drug-eluting stents 
(n=4300)*
Trials with 
newer-generation 
drug-eluting stents 
(n=3969)*
p value
Age (years) 60·8 (10·1; 3051) 64·7 (9·6; 8467) p<0·0001 63·8 (9·5; 4300) 65·7 (9·6; 3969) p<0·0001
Sex
Female 23·2% (707/3051) 24·1% (2037/8467) p=0·32 25·3% (1087/4300) 23·9% (948/3969) p=0·14
Male 76·8% (2344/3051) 75·9% (6430/8467) p=0·32 74·7% (3213/4300) 76·1% (3021/3969) p=0·14
Body-mass index >30 kg/m² 22·3% (578/2593) 30·0% (2528/8424) p<0·0001 32·4% (1388/4290) 25·6% (1010/3939) p<0·0001
Current smoker 27·5% (843/3049) 20·4% (1704/8355) p<0·0001 19·6% (833/4260) 21·2% (827/3900) p=0·064
Diabetes 17·8% (543/3051) 45·4% (3843/8467) p<0·0001 59·2% (2544/4300) 27·7% (1101/3969) p<0·0001
Insulin treated 3·4% (48/1396) 14·1% (1001/7083) p<0·0001 19·0% (816/4299) 6·6% (185/2784) p<0·0001
Hypertension 51·1% (1558/3051) 73·9% (6235/8436) p<0·0001 76·5% (3278/4287) 70·1% (2770/3954) p<0·0001
Hypercholesterolaemia 58·3% (1776/3047) 72·1% (6068/8414) p<0·0001 75·4% (3230/4285) 69·2% (2727/3938) p<0·0001
Peripheral vascular disease 7·6% (233/3051) 8·7% (631/7271) p=0·081 9·2% (396/4300) 7·5% (208/2776) p=0·0116
Carotid artery disease 5·6% (25/450) 8·2% (304/3696) p=0·0479 8·2% (148/1800) 8·2% (156/1896) p=0·99
Previous TIA or CVA 3·3% (47/1438) 6·4% (424/6668) p<0·0001 5·8% (215/3688) 6·8% (189/2782) p=0·11
Previous myocardial 
infarction
42·1% (1285/1766) 21·7% (1570/7243) p<0·0001 25·8% (1105/4280) 13·9% (384/2768) p<0·0001
Left-ventricular ejection fraction
Moderate (30–49%) 16·1% (442/2746) 14·3% (1144/7987) p=0·0239 15·7% (668/4242) 11·9% (425/3568) p<0·0001
Poor (<30%) 0·1% (4/2746) 1·2% (99/7987) p<0·0001 1·6% (66/4242) 0·6% (21/3568) p<0·0001
Unstable angina pectoris 41·2% (850/2063) 32·7% (2703/8255) p<0·0001 31·8% (1369/4287) 33·7% (1334/3955) p=0·067
Three-vessel disease† 41·9% (1280/3051) 70·6% (3774/5348) p<0·0001 69·4% (2976/4287) 77·2% (679/3969) p<0·0001
Left main disease 1·0% (29/3051) 52·5% (4449/8467) p<0·0001 30·5% (1313/4300) 79·0% (3136/3969) p<0·0001
Follow-up (years) 4·7 (1·0; 2795) 3·5 (1·4; 7726) p<0·0001 4·0 (1·4; 3830) 3·1 (1·2; 3723) p<0·0001
Data are mean (SD; n) or % (n/N). TIA=transient ischaemic attack. CVA=cerebrovascular attack. PCI=percutaneous coronary intervention. *The VA CARDS trial7 was excluded from 
the analysis of first-generation and newer-generation drug-eluting stents because a mixture of these stents was used. †Of the group of patients with multivessel disease.
Table 3: Differences in patient characteristics according to whether trials did PCI with bare-metal or drug-eluting stents
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matching to compare CABG with PCI using drug-eluting 
stents for multivessel disease to find differences in 
survival with larger sample sizes.24,25 The ASCERT study,25 
the largest of such analyses, reported an adjusted 4 year 
mortality of 16·4% for CABG and 20·8% for PCI with 
first-generation drug-eluting stents in a cohort of patients 
aged 65 years or older; mortality was consistent across 
multiple subgroups. Notably, the survival curves of CABG 
and PCI in this study are similar to those of the ASCERT 
study: PCI shows a benefit within the first year of follow-
up, but a larger benefit is seen with CABG than with PCI 
with longer follow-up. We showed that this reversal of 
risk resulted in a benefit for CABG over PCI at a mean 
follow-up of 4·1 years, which might become larger with 
longer follow-up given that the HR favoured CABG at 
later follow-up in time-varying models.
In the SYNTAX trial,26 5 year mortality was similar for 
CABG and PCI with paclitaxel-eluting, first-generation 
drug-eluting stents in patients with left main disease. Two 
major trials9,10 have since focused on finding the optimal 
revascularisation strategy for left main disease and have 
reported conflicting outcomes of CABG versus PCI. The 
EXCEL trial10 reported that PCI was non-inferior to CABG 
after 3 years, whereas the NOBLE trial9 did not show non-
inferiority for PCI versus CABG at 5 years. The differences 
in timing and composition of the primary endpoints make 
comparing these trials difficult and presumably explain 
the apparent difference in results. 3 year individual 
endpoints in the NOBLE trial were later confirmed to be 
similar to those in the EXCEL trial.27 In our pooled analysis 
of data for patients with left main disease from four 
different trials, mortality was similar after CABG and PCI 
at 5 years’ follow-up. Unlike for patients with multivessel 
disease, the similarity in mortality in patients with left 
main disease was consistent in a subgroup analysis 
according to diabetes status, although this difference 
might be due to the smaller sample size in the diabetic 
subgroup of patients with left main disease. Coronary 
complexity did not affect mortality in patients with left 
main disease, although patients with a high SYNTAX 
score were relatively under-represented because of specific 
inclusion criteria (eg, in the EXCEL trial) and a preference 
of heart teams for CABG.19 Therefore, the degree of 
complexity should still be considered when proposing a 
specific treatment for individual patients with left main 
disease. Patients with a complex left main lesion and 
three-vessel disease with a high SYNTAX score might 
still benefit from CABG in terms of mortality, as 
well as incidence of myocardial infarction and repeat 
revascularisation, whereas patients with a non-complex 
lesion and one-vessel or two-vessel disease might be 
excellent candidates for PCI. Clinical guidelines have not 
Figure 2: Mortality after CABG versus after PCI during 5 years’ follow-up, by subgroup
Kaplan-Meier estimates are from the overall pooled patient population. PCI=percutaneous coronary intervention. CABG=coronary artery bypass grafting. HR=hazard 
ratio. SYNTAX=Synergy between PCI with Taxus and Cardiac Surgery.
HR (95% CI) p value pinteraction
Sex
 Male
 Female
Age at baseline (years)
 <65
 ≥65
Body-mass index (kg/m2)
 <30
 ≥30
Hypertension
 Yes
 No
Hypercholesterolaemia
 Yes
 No
Diabetes
 Yes
 No
Peripheral vascular disease
 Yes
 No
Previous myocardial infarction
 Yes
 No
Left-ventricular ejection fraction
 ≥50%
 30–49%
 <30%
SYNTAX score
 0–22
 23–32
 ≥33
 1·20 (1·03–1·39) 0·0181 0·82
 1·23 (0·97–1·57) 0·0854
 1·23 (1·00–1·51) 0·0534 0·98
 1·19 (1·02–1·40) 0·0284
 1·20 (1·04–1·40) 0·0156 0·43
 1·35 (1·05–1·73) 0·0179
 1·16 (1·00–1·34) 0·0527 0·25
 1·37 (1·06–1·76) 0·0144
 1·19 (1·02–1·39) 0·0272 0·76
 1·24 (1·00–1·55) 0·0527
 1·44 (1·20–1·74) 0·0001 0·0077
 1·02 (0·86–1·21) 0·81
 1·35 (0·96–1·90) 0·0869 0·66
 1·21 (1·05–1·39) 0·0094
 1·21 (0·97–1·50) 0·0852 0·97
 1·22 (1·03–1·44) 0·0180
 1·14 (0·98–1·32) 0·0974 0·65
 1·41 (1·08–1·84) 0·0122
 1·25 (0·64–2·46) 0·52
 1·02 (0·77–1·34) 0·91 0·21
 1·20 (0·94–1·51) 0·14
 1·52 (1·15–2·02) 0·0029      
 387/4380 (10·7%) 318/4394 (8·8%)
 152/1373 (12·7%) 119/1371 (10·6%)
 200/2971 (8·0%) 160/2940 (6·4%)
 339/2782 (14·8%) 277/2825 (12·5%)
 373/3958 (11·2%) 304/3953 (9·4%)
 148/1548 (12·1%) 106/1558 (8·6%)
 391/3880 (12·2%) 332/3913 (10·6%)
 145/1859 (9·1%) 103/1835 (6·6%)
 364/3982 (11·0%) 288/3862 (9·1%)
 173/1744 (11·6%) 148/1873 (9·5%)
 278/2215 (15·7%) 185/2171 (10·7%)
 261/3538 (8·7%) 252/3594 (8·4%)
 75/424 (20·7%) 58/440 (16·0%)
 428/4734 (10·6%) 346/4724 (8·7%)
 183/1438 (14·2%) 146/1417 (11·6%)
 318/3700 (10·2%) 257/3739 (8·4%)
 356/4447 (9·6%) 311/4597 (8·3%)
 132/807 (19·3%) 95/779 (15·1%)
 18/49 (57·3%) 16/54 (34·4%)
 105/1533 (8·8%) 100/1585 (8·1%)
 163/1677 (12·4%) 122/1545 (10·9%)
 117/871 (16·5%) 83/927 (11·6%)      
PCI CABG
10·5 32
Favours CABGFavours PCI
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been revised since the release of data from the EXCEL and 
NOBLE trials. Based on existing data of similar mortality 
with the two interventions, the indication for PCI with 
contemporary drug-eluting stents might be broadened 
to patients with more complex left main disease (eg, 
intermediate SYNTAX scores). However, given that only 
978 patients with left main disease in our cohort had high 
SYNTAX scores, additional data are required before PCI 
can be routinely recommended in patients with complex 
left main disease. Longer follow-up is essential to better 
define differences in survival between CABG and PCI, 
because landmark analyses from the EXCEL trial10 showed 
that the risk of mortality after CABG and PCI was different 
according to follow-up duration and might show a benefit 
for CABG with longer follow-up.
The main strength of this study is that we were able 
to identify clinically relevant differences in all-cause 
mortality between CABG and PCI because of collaboration 
with the principal investigators of 11 high-quality 
randomised trials. This collaboration allowed data to be 
pooled to provide sufficient power to examine an outcome 
that occurs reasonably infrequently. Indeed, all-cause 
mortality is considered to be the most clinically important 
and least biased endpoint, which is another strength of 
this analysis. Access to individual patient data facilitated 
analysis of outcomes in important subgroups and 
construction of Kaplan-Meier curves so that temporal 
associations between the interventions and mortality 
could be examined.
Nevertheless, this study has several limitations. First, 
all the included trials assumed clinical equipoise 
between CABG and PCI. These trials had specific 
inclusion and exclusion criteria, and many patients were 
excluded because CABG or PCI was thought to be the 
preferred revascularisation strategy based on the age, 
risk profile, or coronary complexity of the individual.19 
These criteria  and the selection of patients resulted in 
only 22·1% of patients having a SYNTAX score of 33 or 
higher. Second, the inclusion and exclusion criteria led 
to significant heterogeneity in the baseline characteristics 
of patients from different trials, as shown by our 
assessment of frailty. Third, besides mortality, other 
outcomes that affect morbidity and quality of life, 
such as myocardial infarction, stroke, and repeat 
revascularisation, are important for the patient and 
should be considered by heart teams when deciding on 
the best revascularisation option for each patient. In an 
era of exponentially growing health-care costs, with a 
need to reduce expenses, the cost-effectiveness of PCI 
and CABG should also be evaluated. Fourth, the mean 
Figure 3: Mortality after CABG versus after PCI during 5 years’ follow-up of patients with (A) or without (B) diabetes and with left main disease (C) or 
multivessel disease (D)
Kaplan-Meier estimates are from the overall pooled patient population. PCI=percutaneous coronary intervention. CABG=coronary artery bypass grafting. HR=hazard ratio.
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patient age was about 64 years, and the mean follow-up 
was 3·8 years. In view of the reasonably long life 
expectancy of patients with coronary artery disease, this 
follow-up is still too short to establish the full effect of 
the revascular isation method on survival, particularly 
considering the diverging or converging Kaplan-Meier 
curves in specific subgroups. Fifth, definitions and 
reporting of patient characteristics might have slightly 
differed between trials, which could have affected the 
results of the subgroup analyses and meant that we were 
unable to do a subgroup analysis according to renal 
function. Sixth, we could not include data from the 
LE MANS trial,14 although it is very unlikely that 
inclusion of these 105 patients with left main disease 
would have substantially altered the results, and thus 
the out comes of this study are robust with respect to the 
available evidence.
In conclusion, we showed that 5 year mortality was 
significantly lower after CABG than after PCI. In particular, 
the benefit of CABG over PCI was shown in patients with 
multivessel disease and diabetes, but not in patients with 
multivessel disease without diabetes. Nor was there a 
benefit for CABG or PCI in patients with left main disease. 
Consideration of coronary lesion complexity is important 
when choosing the appropriate revascularisation strategy. 
Longer follow-up is needed to better define mortality 
differences between the interventions.
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